{'fraction_non_alphanumeric': 0.019165727170236752, 'fraction_numerical': 0.0011273957158962795, 'mean_word_length': 5.481751824817518, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Management of Behçet's syndrome

Purpose of reviewThere is agreement that the management of Behçet's syndrome has recently improved, especially with the wider use of biologics. The aim of this review is to summarize the current management strategies in Behçet's syndrome. Recent findingsThere is growing experience with tumor necrosis factor-alpha antagonists in the management of eye gastrointestinal and nervous disease in Behçet's syndrome. Interferon-alpha at lower doses may increase its tolerability. Other biologics such as interleukin 1-blocking agents and tocilizumab were used in a small number of patients and also seem to be effective. SummaryAlthough experiences with biologics have expanded and looks promising, this is mostly observational or retrospective. There still is a lack of controlled trials with these agents, especially in patients with major organ involvement.